← Back to headlines
Krystal Biotech Beats Q4 Top-Line and Bottom-Line Estimates, Initiates FY26 Outlook
Krystal Biotech exceeded both revenue and earnings estimates for the fourth quarter and has initiated its financial outlook for fiscal year 2026.
17 Feb, 12:04 — 17 Feb, 12:04
ℹOnly 1 source covers this story
Read at source (1 outlet)
Related Stories
Investing $3,000 Into These 3 Ultra-High-Yielding Dividend Stocks Could Generate Hundreds of Dollars in Annual Passive Income
just now
Nvidia stock hits this bizarre valuation level
just now
ROBLOX (RBLX) Stock Falls Amid Concerns Over Sustaining Momentum
just now
Artisan Mid Cap Fund Sells Snowflake (SNOW) Due to High Valuation
just now